Zacks: Brokerages Anticipate Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) to Post -$0.19 Earnings Per Share

Wall Street analysts expect Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) to announce earnings of ($0.19) per share for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Aurinia Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.14) and the lowest estimate coming in at ($0.27). Aurinia Pharmaceuticals posted earnings per share of ($0.21) in the same quarter last year, which would indicate a positive year-over-year growth rate of 9.5%. The company is scheduled to issue its next earnings report on Thursday, November 14th.

On average, analysts expect that Aurinia Pharmaceuticals will report full-year earnings of ($0.68) per share for the current financial year, with EPS estimates ranging from ($0.72) to ($0.58). For the next fiscal year, analysts anticipate that the company will post earnings of ($0.69) per share, with EPS estimates ranging from ($1.09) to ($0.31). Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). Aurinia Pharmaceuticals had a negative return on equity of 50.08% and a negative net margin of 13,231.97%. The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.05 million.

A number of equities analysts have weighed in on AUPH shares. Bloom Burton reaffirmed a “buy” rating on shares of Aurinia Pharmaceuticals in a research report on Wednesday, October 2nd. Citigroup initiated coverage on Aurinia Pharmaceuticals in a research note on Monday, September 9th. They set an “outperform” rating and a $14.00 price objective on the stock. Oppenheimer initiated coverage on Aurinia Pharmaceuticals in a research note on Tuesday, September 10th. They set an “outperform” rating and a $14.00 price objective on the stock. Royal Bank of Canada reiterated a “buy” rating and set a $11.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Thursday, August 8th. Finally, BidaskClub cut Aurinia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, October 3rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. Aurinia Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $15.18.

Institutional investors have recently made changes to their positions in the company. Toronto Dominion Bank raised its stake in shares of Aurinia Pharmaceuticals by 26.3% during the 2nd quarter. Toronto Dominion Bank now owns 12,355 shares of the biotechnology company’s stock worth $81,000 after purchasing an additional 2,575 shares in the last quarter. UBS Asset Management Americas Inc. bought a new stake in shares of Aurinia Pharmaceuticals during the 2nd quarter worth approximately $88,000. A.R.T. Advisors LLC raised its stake in shares of Aurinia Pharmaceuticals by 44.9% during the 2nd quarter. A.R.T. Advisors LLC now owns 18,395 shares of the biotechnology company’s stock worth $121,000 after purchasing an additional 5,700 shares in the last quarter. Point72 Asset Management L.P. raised its stake in Aurinia Pharmaceuticals by 670.2% in the 2nd quarter. Point72 Asset Management L.P. now owns 22,083 shares of the biotechnology company’s stock valued at $145,000 after acquiring an additional 19,216 shares during the period. Finally, Vanguard Group Inc. raised its stake in Aurinia Pharmaceuticals by 18.6% in the 2nd quarter. Vanguard Group Inc. now owns 29,020 shares of the biotechnology company’s stock valued at $191,000 after acquiring an additional 4,549 shares during the period. Institutional investors own 31.12% of the company’s stock.

NASDAQ:AUPH opened at $5.01 on Friday. Aurinia Pharmaceuticals has a twelve month low of $3.52 and a twelve month high of $7.85. The business has a 50 day moving average price of $5.42 and a two-hundred day moving average price of $6.05.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Recommended Story: What is the price-sales ratio?

Get a free copy of the Zacks research report on Aurinia Pharmaceuticals (AUPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.